Gambaran Terapi dan Luaran Klinik Bedaquiline Pada Pasien MDR TB di RSUP Dr Kariadi Semarang

Niken Puspitasari; Ika Puspitasari; Titik Nuryastuti

doi:10.22146/farmaseutik.v20i1.77632

Gambaran Terapi dan Luaran Klinik Bedaquiline Pada Pasien MDR TB di RSUP Dr Kariadi Semarang

https://doi.org/10.22146/farmaseutik.v20i1.77632

Niken Puspitasari⁽¹⁾, Ika Puspitasari^(2*), Titik Nuryastuti⁽³⁾

(1) Mahasiswa Magister Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada
(2) Fakultas Farmasi, Universitas Gadjah Mada
(3) Rumah Sakit Akademik, Universitas Gadjah Mada
(*) Corresponding Author

Abstract

Tuberkulosis (TB) merupakan penyakit infeksi penyebab kematian terbanyak di dunia. Bedaquiline adalah antimikroba baru yang mempunyai aktivitas spesifik melawan Mycobacterium tuberculosis. Tujuan penelitian ini untuk mengetahui gambaran terapi dan luaran klinik Bedaquiline pada pasien MDR TB di RSUP Dr Kariadi Semarang. Subyek penelitian yaitu pasien MDR TB di RSUP Dr. Kariadi Semarang periode 1 Januari 2017 sampai dengan 31 Juli 2021. Analisis data dilakukan secara deskriptif menggunakan metode univariat meliputi data karakteristik subyek, gambaran penggunaan obat, luaran klinik pasien. Terdapat 125 pasien MDR TB yang memenuhi kriteria inklusi dan eksklusi. Rata-rata usia pasien 46,6 tahun ± 13,1 tahun; 57,6% merupakan laki-laki; 53,6% berpendidikan SMA; 67,2% pasien mempunyai pekerjaan; 8,2% pasien berstatus menikah; dan 88,0% pasien mempunyai IMT normal. Jenis obat tuberkulosis yang paling banyak digunakan bersamaan dalam regimen mengandung Bedaquiline yaitu Clofazimin (87,2%), Cycloserin dan Ethambutol (82,4%), Pyrazinamid (80,8%), Isoniazid (69,6%), Ethionamid (65,6%), Levofloxacin (64,8%) dan Linezolid (48,8%). Pasien mengalami konversi kultur sputum rata-rata 52,2 hari dengan SD 42 hari. Tingkat keberhasilan terapi mencapai 74,4% (pasien sembuh 73,6% dan pengobatan lengkap 0,8%). Pasien yang meninggal dunia sebanyak 18 pasien (14,4%); putus berobat 8 pasien (6,4%); dan gagal pengobatan 6 pasien (4,8%).

Keywords

Bedaquiline; Luaran Klinik; MDR TB

Full Text:

PDF

References

1. Cameron LH, Starke JR. Tuberculosis (Mycobacterium tuberculosis). In: Nelson Textbook of Pediatrics. Vol 242. 21st ed. Elsevier; 2020:1565-1582. Accessed September 13, 2021. https://www-clinicalkey-com.ezproxy.ugm.ac.id/#!/content/book/3-s2.0-B978032352950100242X

2. World Health Organization. Global Tuberculosis Report 2020. World Health Organization; 2020:32.

3. Dinkes Provinsi Jawa Tengah. Buku Saku Kesehatan Tahun 2019. Dinkes Provinsi Jawa Tengah; 2020.

4. Palomino JC, Martin A. TMC207 becomes bedaquiline, a new anti-TB drug. Future Microbiol. 2013;8(9):1071-1080.

5. Cox E, Laessig K. FDA Approval of Bedaquiline — The Benefit–Risk Balance for Drug-Resistant Tuberculosis. N Engl J Med. 2014;371(8):689-691.

6. Kementerian Kesehatan RI. Peraturan Menteri Kesehatan Republik Indonesia No. 67 Tahun 2016 Tentang Penanggulangan Tuberkulosis. Kemenkes RI; 2016.

7. Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J. 2017;49(5):1700387.

8. Mbuagbaw L, Guglielmetti L, Hewison C, et al. Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis. Emerg Infect Dis. 2019;25(5):11.

9. Mase S, Chorba T, Parks S, et al. Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States. Clin Infect Dis Off Publ Infect Dis Soc Am. 2020;71(4):1010-1016.

10. Wang MG, Wu SQ, He JQ. Efficacy of bedaquiline in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):970.

11. Zhurkin D, Gupta RK, Gadoev J, et al. Effectiveness and safety of bedaquiline-containing regimens among adults with multidrug- or extensively drug-resistant pulmonary TB in Belarus: a nationwide cohort study. 2019;5(4):9.

12. Anderson LF, Tamne S, Watson JP, et al. Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2013;18(40):20601.

13. Widyasrini ER, Masters Program in Family Medicine, Sebelas Maret University, Probandari AN, Faculty of Medicine, Sebelas Maret University, - R, Department of Pulmonology and Respiratory Medicine, Dr. Moewardi, Surakarta. Factors Affecting the Success of Multi Drug Resistance (MDR-TB) Tuberculosis Treatment in Residential Surakarta. J Epidemiol Public Health. 2017;02(01):45-57.

14. Ibrahim LM, Hadejia IS, Nguku P, et al. Factors associated with interruption of treatment among Pulmonary Tuberculosis patients in Plateau State, Nigeria. 2011. Pan Afr Med J. 2014;17:78.

15. Kondoy PPH, Rombot DV, Palandeng HMF, Pakasi TA. Faktor-Faktor Yang Berhubungan Dengan Kepatuhan Berobat Pasien Tuberkulosis Paru di Lima Puskesmas di Kota Manado. J Kedokt KOMUNITAS DAN Trop. 2014;2(1). Accessed August 2, 2022. https://ejournal.unsrat.ac.id/index.php/JKKT/article/view/4038

16. Aibana O, Bachmaha M, Krasiuk V, et al. Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine. BMC Infect Dis. 2017;17(1):129.

17. Kuchukhidze G, Kumar AMV, de Colombani P, et al. Risk factors associated with loss to follow-up among multidrug-resistant tuberculosis patients in Georgia. Public Health Action. 2014;4(Suppl 2):S41-S46.

18. Tupasi TE, Garfin AMCG, Kurbatova EV, et al. Factors Associated with Loss to Follow-up during Treatment for Multidrug-Resistant Tuberculosis, the Philippines, 2012–2014. Emerg Infect Dis. 2016;22(3):491-502.

19. Diallo A, Diallo BD, Camara LM, et al. Different profiles of body mass index variation among patients with multidrug-resistant tuberculosis: a retrospective cohort study. BMC Infect Dis. 2020;20:315.

20. Wallis RS. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. Eur Respir J. 2016;48(5):1526-1527.

21. Kervezee L, Gotta V, Stevens J, et al. Levofloxacin‐Induced QTc Prolongation Depends on the Time of Drug Administration. CPT Pharmacomet Syst Pharmacol. 2016;5(9):466-474.

22. Teng C, Walter EA, Gaspar DKS, Obodozie-Ofoegbu OO, Frei CR. Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System. Int J Med Sci. 2019;16(7):1018-1022.

DOI: https://doi.org/10.22146/farmaseutik.v20i1.77632